期刊
JOURNAL OF THE AMERICAN HEART ASSOCIATION
卷 10, 期 16, 页码 -出版社
WILEY
DOI: 10.1161/JAHA.120.020196
关键词
cardiovascular disease; death; fibroblast growth factor 23; heart failure; phosphorus
资金
- American Heart Association Strategically Focused Research Network in Disparities in Cardiovascular Disease [15SFDRN25080331]
- National Heart, Lung, and Blood Institute
- University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]
- Northwestern University [HHSN268201300027C]
- University of Minnesota [HHSN268201300028C]
- Kaiser Foundation Research Institute [HHSN268201300029C]
- Johns Hopkins University School of Medicine [HHSN268200900041C]
- Intramural Research Program of the National Institute on Aging (NIA)
- National Institute on Aging
- National Heart, Lung, and Blood Institute [AG0005, K24HL150235]
- National Institute of Diabetes and Digestive and Kidney Diseases [K24DK116180, R01DK110087]
- National Institutes of Health's National Center for Advancing Translational Sciences [KL2TR001424]
In middle-aged adults with few comorbidities, higher levels of fibroblast growth factor 23 (FGF23) were not independently associated with greater risk of cardiovascular events or death. Higher cFGF23 was independently associated with greater risk of heart failure hospitalization.
Background Higher circulating fibroblast growth factor 23 (FGF23) associates with greater risk of cardiovascular disease (CVD) and mortality in older adults. The association of FGF23 with cardiovascular outcomes in younger populations has been incompletely explored. Methods and Results We measured C-terminal FGF23 (cFGF23) and intact FGF23 (iFGF23) in 3151 middle-aged adults (mean age, 45 +/- 4) who participated in the year 20 examination of the CARDIA (Coronary Artery Risk Development in Young Adults) study. We used separate Cox proportional hazards models to examine the associations of cFGF23 and iFGF23 with incident CVD and mortality, adjusting models sequentially for sociodemographic, clinical, and laboratory factors. A total of 157 incident CVD events and 135 deaths occurred over a median 7.6 years of follow-up (interquartile range, 4.1-9.9). In fully adjusted models, there were no statistically significant associations of FGF23 with incident CVD events (hazard ratio per doubling of cFGF23: 1.14, 95%CI 0.97,1.34; iFGF23: 0.76, 95%CI 0.57,1.02) or all-cause mortality (hazard ratio per doubling of cFGF23, 1.17; 95% CI, 1.00-1.38; iFGF23, 0.86; 95% CI, 0.64-1.17). In analyses stratified by CVD subtypes, higher cFGF23 was associated with greater risk of heart failure hospitalization (hazard ratio per doubling of cFGF23, 1.52; 95% CI, 1.18-1.96) but not coronary heart disease or stroke, whereas iFGF23 was not associated with CVD subtypes in any model. Conclusions In middle-aged adults with few comorbidities, higher cFGF23 and iFGF23 were not independently associated with greater risk of CVD events or death. Higher cFGF23 was independently associated with greater risk of heart failure hospitalization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据